#$LBRX
November 9, 2026 at 2:25 PM
LB Pharmaceuticals $LBRX reported Q3 2026 EPS of -$1.79, missing the -$1.60 estimate by 11.9%. Revenue was $0. No analyst estimate was published for revenue.

https://fundspec.ai/s/LBRX/earnings
Momentum scores on thousands of tickers, refreshed every night.
November 5, 2026 at 11:00 PM
🚨 $LBRX
On November 5, 2026, LB Pharmaceuticals Inc issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is bein...
SEC Filing: LBRX
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 9:35 PM
#$LBRX weekly close $39.70 (+2.5% w/w), below SMA50 $41.38 / above SMA200 $32.57, RSI 52.9. Range $33.13-$41.58.

LBRX Stock Hub: LB Pharmaceuticals News, LB-102 and Schizophrenia
www.merlintrader.com/lb-pharmaceu...
LBRX Stock: LB Pharmaceuticals News, LB-102 & Trials
LB Pharmaceuticals stock news and analysis: LB-102 evidence, NOVA studies, resources, recent financing and the pivotal-trial and tolerability risks for LBRX.
www.merlintrader.com
November 1, 2026 at 9:02 PM
🚨 $LBRX
Miller Joseph M (Chief Financial Officer) reported special transactions (Non-P/S).
SEC Filing: LBRX
Click to view the official SEC document.
www.sec.gov
October 13, 2026 at 8:14 PM
🚨 $LBRX
Kozauer Susan Gani (Chief Medical Officer) reported special transactions (Non-P/S).
SEC Filing: LBRX
Click to view the official SEC document.
www.sec.gov
October 13, 2026 at 8:14 PM
LB Pharmaceuticals ($LBRX): 13G holder trims
Jpmorgan Chase: 5.2% → 4.3% (about $50M)
1,497,293 → 1,401,790 shares
SEC Schedule 13G/A · filed Oct 13
#Investing #Stocks

Visit for more info: www.elixstocks.com
Educational only. Not investment advice.
Jpmorgan Chase & Co: 4.3% of LB Pharmaceuticals ($LBRX)
Schedule 13G/A filed Oct 13. Who filed, the stake, and how it changed.
elixstocks.com
October 13, 2026 at 5:48 PM
LB Pharmaceuticals $LBRX Stock: LB-102 Phase 3 Trial

Explore the clinical evidence, development plans and financial risks in our research hub.
https://www.merlintrader.com/lb-pharmaceuticals-stock-hub/
LB Pharmaceuticals $LBRX Stock: LB-102 Phase 3 Trial
LB Pharmaceuticals $LBRX research: LB-102 clinical evidence, NOVA-2 and mood-disorder trials, cash runway, dilution and development risks.
www.merlintrader.com
October 10, 2026 at 8:17 PM
JPMorgan, Raymond James and Canaccord started coverage on #$CCCC, #$DFTX, #$PALI and #$LBRX. notreload.xyz/xy/pali-lbrx...
PALI, LBRX, CCCC, DFTX: New Buy Ratings and Upside
Targets imply 88% to 314% upside, with cash into 2027-2030.
notreload.xyz
October 9, 2026 at 12:35 PM
October 5, 2026 at 1:41 PM
🚨 $LBRX
Kozauer Susan Gani (Chief Medical Officer) filed Form 3 reporting no initial stock ownership.
SEC Filing: LBRX
Click to view the official SEC document.
www.sec.gov
September 24, 2026 at 8:40 PM
🚨 $LBRX
On September 15, 2026, the Company issued a press release announcing the appointment of Dr. Kozauer as the Company’s Chief Medical Officer.
SEC Filing: LBRX
Click to view the official SEC document.
www.sec.gov
September 15, 2026 at 12:06 PM
🚨 $LBRX
On September 3, 2026, the Company issued a press release announcing the appointment of Mr. Miller as the Company’s Chief Financial Officer.
SEC Filing: LBRX
Click to view the official SEC document.
www.sec.gov
September 3, 2026 at 12:05 PM
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals (LBRX) appointed Joseph Miller as Chief Financial Officer, bringing more than 20 years of biopharmaceutical finance and operational leadership experience to the company.The company highlights Miller’s track record in scaling infrastructure and teams to support organizational growth, commercialization and long-term value creation. Management ties his appointment to a “potentially transformative period” as LB Pharmaceuticals approaches pivotal NOVA-2 clinical trial results and continues preparations for the potential launch of LB-102 in schizophrenia.Miller most recently served as CFO of Aurinia Pharmaceuticals, where he built and scaled finance and operations during the transition from late-stage development to the commercial launch of LUPKYNIS for active lupus nephritis, overseeing revenue growth, profitability and an ex-U.S. licensing and collaboration agreement with Otsuka Pharmaceutical. His prior roles include CFO and senior leadership positions at Avalo Therapeutics, Sucampo Pharmaceuticals, QIAGEN, Eppendorf and KPMG LLP.
www.stocktitan.net
September 3, 2026 at 12:00 PM
LBRX debuts as public biotech with Phase 3 schizophrenia trial underway, $395M raised

$LBRX 10-K → https://filingdiff.com/ticker/LBRX/0001193125-26-126368/
June 11, 2026 at 5:40 PM
LBRX reports $19M Q1 loss advancing Phase 3 schizophrenia trial; material control weaknesses persist

$LBRX 10-Q → https://filingdiff.com/ticker/LBRX/0001193125-26-219607/
June 10, 2026 at 10:10 PM
LB Pharmaceuticals to Present at 25th Needham Conference: LB Pharmaceuticals (Nasdaq: LBRX) will present at the 25th Needham Virtual Healthcare Conference after its Apr 9, 2026 release; watch for… 👈 Read full analysis #LBPharmaceuticals #NeedhamConference #Healthcare #Pharmaceuticals #Investing
LB Pharmaceuticals to Present at 25th Needham Conference
LB Pharmaceuticals (Nasdaq: LBRX) will present at the 25th Needham Virtual Healthcare Conference after its Apr 9, 2026 release; watch for timeline disclosures and potential re-rating.
dlvr.it
April 9, 2026 at 8:35 PM
Link to the original video: youtube.com/shorts/LbrX-...
June 9, 2025 at 10:05 AM
July 7, 2026 at 4:41 PM
April 27, 2026 at 4:05 PM